By extension, these findings argue that targeted augmentation of MKP-1 activity could be used to treat neurodegenerative conditions or acute brain injury by promoting the neurogenic potential of endogenous or transplanted stem progenitors [42,43]. Here, DUSP1 is linked to injury.